Table 5.

Absolute and categorical changes in weight, total cholesterol, triglycerides, LDL, HDL, and glucose

	Placebo		Olanzapine		p Value
	n	LS mean (SE)	n	LS mean (SE)
Weight gain, kg	52	−0.36 (0.29)	104	+2.12 (0.21)	<.001
		n/N (%)		n/N (%)
Patients with significant weight gain (≥7% body weight)		1/52 (1.9)		21/104 (20.2)	.001
	n	LS mean (SE)	n	LS mean (SE)
Baseline-to-endpoint change in fasting laboratory values
Cholesterol, mg/dL	52	−0.96 (3.37)	104	+10.06 (2.38)	.008
Triglycerides, mg/dL	52	−4.17 (12.31)	104	+30.67 (8.68)	.02
LDL, mg/dL	51	−1.06 (3.07)	103	+8.78 (2.16)	.01
HDL, mg/dL	52	+1.10 (1.27)	104	−2.99 (0.90)	.01
Glucose, mg/dL	51	−1.02 (1.11)	100	+ 1.01 (0.79)	.14
		n/N (%)		n/N (%)
Patients with categorical shifts in fasting cholesterol values
Normal to borderline		2/17 (11.8)		13/39 (33.3)	.11
Normal to high		0/17 (0.0)		1/39 (2.6)	1.00
Borderline to high		0/25 (0.0)		13/52 (25.0)	.007
Patients with categorical shifts in fasting triglyceride values
Normal to borderline		3/37 (8.1)		5/82 (6.1)	.70
Normal to high		1/37 (2.7)		9/82 (11.0)	.17
Normal to extremely high		0/37 (0.0)		0/82 (0.0)	--
Borderline to high		1/9 (11.1)		3/12 (25.0)	.60
Borderline to extremely high		0/9 (0.0)		0/12 (0.0)	--
Patients with categorical shifts in fasting LDL cholesterol values
Normal to borderline		4/9 (44.4)		11/26 (42.3)	>.99
Normal to high		0/9 (0.0)		0/26 (0.0)	--
Borderline to high		0/34 (0.0)		6/68 (8.8)	.18
Patients with categorical shifts in fasting HDL cholesterol values
Normal to low		0/46 (0.0)		8/97 (8.2)	.05
Patients with categorical shifts in fasting glucose values
Normal to impaired		5/32 (15.6)		9/72 (12.5)	.76
Impaired to high		0/18 (0.0)		2/28 (7.1)	.51
Normal/impaired to high		0/50 (0.0)		3/100 (3.0)	.55
Normal to high		0/32 (0.0)		1/72 (1.4)	1.00

Abbreviations: HDL = high-density lipoprotein; LDL = low-density lipoprotein; LS mean = least squares mean; SE = standard error.